Menu
GeneBe

FAS

Fas cell surface death receptor, the group of CD molecules|Tumor necrosis factor receptor superfamily|Death inducing signaling complex

Basic information

Region (hg38): 10:88953812-89029605

Previous symbols: [ "FAS1", "APT1", "TNFRSF6" ]

Links

ENSG00000026103NCBI:355OMIM:134637HGNC:11920Uniprot:P25445AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • autoimmune lymphoproliferative syndrome type 1 (Definitive), mode of inheritance: AD
  • autoimmune lymphoproliferative syndrome (Supportive), mode of inheritance: AD
  • autoimmune lymphoproliferative syndrome type 1 (Moderate), mode of inheritance: AR
  • autoimmune lymphoproliferative syndrome type 1 (Strong), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Autoimmune lymphoproliferative syndrome, type IAAD/ARAllergy/Immunology/Infectious; OncologicLymphoproliferation can be suppressed with medications such as corticosteroids, cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil; BMT/HSCT the only curative treatment for ALPS, has to date mostly been reported in patients with severe clinical findings; Surveillance for manifestations of lymphoproliferation and autoimmunity, and specialized imaging studies to detect malignant transformation may be beneficialAllergy/Immunology/Infectious; Hematologic; Oncologic; Renal4165068; 1386609; 7540117; 8929361; 10709732; 15459302; 20301287

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the FAS gene.

  • Autoimmune lymphoproliferative syndrome type 1 (306 variants)
  • not provided (68 variants)
  • not specified (21 variants)
  • Moyamoya disease (8 variants)
  • Familial thoracic aortic aneurysm and aortic dissection (8 variants)
  • Inborn genetic diseases (8 variants)
  • Multisystemic smooth muscle dysfunction syndrome (8 variants)
  • Autoimmune lymphoproliferative syndrome, type 1a (7 variants)
  • FAS-related condition (3 variants)
  • Splenomegaly (1 variants)
  • LUNG CANCER, SUSCEPTIBILITY TO (1 variants)
  • See cases (1 variants)
  • Inherited Immunodeficiency Diseases (1 variants)
  • Hepatoblastoma (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the FAS gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
38
clinvar
4
clinvar
44
missense
10
clinvar
13
clinvar
113
clinvar
8
clinvar
1
clinvar
145
nonsense
8
clinvar
1
clinvar
9
start loss
0
frameshift
19
clinvar
6
clinvar
25
inframe indel
1
clinvar
2
clinvar
3
splice donor/acceptor (+/-2bp)
10
clinvar
5
clinvar
15
splice region
2
2
11
4
2
21
non coding
1
clinvar
20
clinvar
29
clinvar
36
clinvar
86
Total 48 26 137 75 41

Highest pathogenic variant AF is 0.0000131

Variants in FAS

This is a list of pathogenic ClinVar variants found in the FAS region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
10-88989499-G-A LUNG CANCER, SUSCEPTIBILITY TO • not specified Benign (Jan 24, 2024)16517
10-88990206-A-G Autoimmune lymphoproliferative syndrome type 1 Benign (Dec 06, 2020)779595
10-88990523-TCC-T Familial thoracic aortic aneurysm and aortic dissection • Moyamoya disease • Multisystemic smooth muscle dysfunction syndrome • Autoimmune lymphoproliferative syndrome type 1 Likely benign (Jun 14, 2016)301514
10-88990530-C-T Autoimmune lymphoproliferative syndrome type 1 • Moyamoya disease • Familial thoracic aortic aneurysm and aortic dissection • Multisystemic smooth muscle dysfunction syndrome Likely benign (Jun 14, 2016)301515
10-88990540-G-A Autoimmune lymphoproliferative syndrome type 1 • Multisystemic smooth muscle dysfunction syndrome • Familial thoracic aortic aneurysm and aortic dissection • Moyamoya disease Uncertain significance (Jun 14, 2016)301516
10-88990582-G-A Multisystemic smooth muscle dysfunction syndrome • Familial thoracic aortic aneurysm and aortic dissection • Autoimmune lymphoproliferative syndrome type 1 • Moyamoya disease Likely benign (Jun 14, 2016)301517
10-88990589-C-T Autoimmune lymphoproliferative syndrome type 1 Uncertain significance (Jan 12, 2018)877879
10-88990703-G-A Multisystemic smooth muscle dysfunction syndrome • Moyamoya disease • Autoimmune lymphoproliferative syndrome type 1 • Familial thoracic aortic aneurysm and aortic dissection Uncertain significance (Jun 14, 2016)301518
10-88990782-G-A Multisystemic smooth muscle dysfunction syndrome • Autoimmune lymphoproliferative syndrome type 1 • Moyamoya disease • Familial thoracic aortic aneurysm and aortic dissection Benign/Likely benign (Jun 14, 2016)301519
10-88990843-A-G Multisystemic smooth muscle dysfunction syndrome • Autoimmune lymphoproliferative syndrome type 1 • Familial thoracic aortic aneurysm and aortic dissection • Moyamoya disease • not specified Benign/Likely benign (Jun 14, 2016)301520
10-88990867-C-A Autoimmune lymphoproliferative syndrome type 1 • Familial thoracic aortic aneurysm and aortic dissection • Moyamoya disease • Multisystemic smooth muscle dysfunction syndrome Uncertain significance (Jun 14, 2016)301521
10-88990880-C-T Autoimmune lymphoproliferative syndrome type 1 Likely benign (Jul 31, 2023)2114880
10-88990891-G-C Autoimmune lymphoproliferative syndrome type 1 Uncertain significance (Sep 01, 2022)2195501
10-88990896-T-C Autoimmune lymphoproliferative syndrome type 1 Likely pathogenic (May 20, 2023)1213255
10-88990903-T-C Autoimmune lymphoproliferative syndrome type 1 Likely benign (Aug 01, 2023)2741677
10-88990908-T-C Autoimmune lymphoproliferative syndrome type 1 • Inborn genetic diseases Conflicting classifications of pathogenicity (Sep 15, 2023)2034063
10-88990912-C-T Autoimmune lymphoproliferative syndrome type 1 Uncertain significance (Jan 12, 2018)878039
10-88990918-C-T Autoimmune lymphoproliferative syndrome type 1 Benign (Jan 22, 2024)878040
10-88990917-T-TCCTGC Autoimmune lymphoproliferative syndrome type 1 Likely benign (Feb 14, 2023)2836781
10-88990925-G-A Autoimmune lymphoproliferative syndrome type 1 Benign (Jan 29, 2024)1601064
10-88990925-G-T Autoimmune lymphoproliferative syndrome type 1 Likely benign (Oct 13, 2023)1655401
10-88990926-G-A Autoimmune lymphoproliferative syndrome type 1 Likely benign (Mar 12, 2022)2104708
10-88991152-C-T not specified Benign (Jan 24, 2024)1284170
10-88991225-T-G not specified Benign (Jan 24, 2024)1229597
10-89003016-T-A Autoimmune lymphoproliferative syndrome type 1 Likely benign (Aug 07, 2023)1966792

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
FASprotein_codingprotein_codingENST00000355740 925129
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.8120.188125734021257360.00000795
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.231211660.7310.000008032214
Missense in Polyphen2253.6880.40977746
Synonymous0.3995558.90.9340.00000300591
Loss of Function3.01214.30.1406.14e-7189

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.00001760.0000176
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death- inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS- mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro). {ECO:0000269|PubMed:19118384, ECO:0000269|PubMed:7533181}.;
Disease
DISEASE: Autoimmune lymphoproliferative syndrome 1A (ALPS1A) [MIM:601859]: A disorder of apoptosis that manifests in early childhood and results in the accumulation of autoreactive lymphocytes. It is characterized by non-malignant lymphadenopathy with hepatosplenomegaly, and autoimmune hemolytic anemia, thrombocytopenia and neutropenia. {ECO:0000269|PubMed:10090885, ECO:0000269|PubMed:10340403, ECO:0000269|PubMed:10515860, ECO:0000269|PubMed:11418480, ECO:0000269|PubMed:17336828, ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:7540117, ECO:0000269|PubMed:8929361, ECO:0000269|PubMed:9028321, ECO:0000269|PubMed:9028957, ECO:0000269|PubMed:9322534, ECO:0000269|PubMed:9821419, ECO:0000269|PubMed:9927496}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Type I diabetes mellitus - Homo sapiens (human);Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human);Allograft rejection - Homo sapiens (human);Graft-versus-host disease - Homo sapiens (human);Non-alcoholic fatty liver disease (NAFLD) - Homo sapiens (human);p53 signaling pathway - Homo sapiens (human);Influenza A - Homo sapiens (human);Autoimmune thyroid disease - Homo sapiens (human);Alzheimer,s disease - Homo sapiens (human);African trypanosomiasis - Homo sapiens (human);TNF signaling pathway - Homo sapiens (human);Chagas disease (American trypanosomiasis) - Homo sapiens (human);Necroptosis - Homo sapiens (human);MAPK signaling pathway - Homo sapiens (human);Natural killer cell mediated cytotoxicity - Homo sapiens (human);Proteoglycans in cancer - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Hepatitis B - Homo sapiens (human);Measles - Homo sapiens (human);Apoptosis - Homo sapiens (human);Cytokine-cytokine receptor interaction - Homo sapiens (human);Human papillomavirus infection - Homo sapiens (human);Herpes simplex infection - Homo sapiens (human);miRNA Regulation of DNA Damage Response;Apoptosis Modulation and Signaling;Alzheimers Disease;Allograft Rejection;Adipogenesis;Nanomaterial induced apoptosis;Integrated Lung Cancer Pathway;Apoptosis;Fas Ligand (FasL) pathway and Stress induction of Heat Shock Proteins (HSP) regulation;Photodynamic therapy-induced AP-1 survival signaling.;Apoptotic Signaling Pathway;TP53 Regulates Transcription of Cell Death Genes;MAPK Signaling Pathway;Apoptosis Modulation by HSP70;VEGFA-VEGFR2 Signaling Pathway;T-Cell antigen Receptor (TCR) Signaling Pathway;DNA Damage Response;Signal Transduction;Gene expression (Transcription);il-2 receptor beta chain in t cell activation;hiv-1 nef: negative effector of fas and tnf;stress induction of hsp regulation;keratinocyte differentiation;Generic Transcription Pathway;Fas;TP53 Regulates Transcription of Cell Death Genes;Regulation of necroptotic cell death;Dimerization of procaspase-8;Regulation by c-FLIP;Ligand-dependent caspase activation;RNA Polymerase II Transcription;Caspase activation via extrinsic apoptotic signalling pathway;Apoptosis;CASP8 activity is inhibited;Regulated Necrosis;Programmed Cell Death;p73 transcription factor network;RIPK1-mediated regulated necrosis;fas signaling pathway (cd95);FasL/ CD95L signaling;Validated transcriptional targets of TAp63 isoforms;Death Receptor Signalling;Transcriptional Regulation by TP53;Direct p53 effectors;Caspase Cascade in Apoptosis;HIV-1 Nef: Negative effector of Fas and TNF-alpha;FAS (CD95) signaling pathway;TP53 Regulates Transcription of Death Receptors and Ligands (Consensus)

Recessive Scores

pRec
0.872

Intolerance Scores

loftool
0.0628
rvis_EVS
0.46
rvis_percentile_EVS
78.46

Haploinsufficiency Scores

pHI
0.0909
hipred
Y
hipred_score
0.671
ghis
0.432

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.597

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Fas
Phenotype
neoplasm; pigmentation phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; respiratory system phenotype; skeleton phenotype; renal/urinary system phenotype; immune system phenotype; vision/eye phenotype; craniofacial phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; digestive/alimentary phenotype; endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype;

Zebrafish Information Network

Gene name
fas
Affected structure
post-vent region
Phenotype tag
abnormal
Phenotype quality
increased curvature

Gene ontology

Biological process
positive regulation of protein phosphorylation;apoptotic process;activation of cysteine-type endopeptidase activity involved in apoptotic process;immune response;signal transduction;regulation of stress-activated MAPK cascade;cellular response to amino acid starvation;Fas signaling pathway;regulation of apoptotic process;positive regulation of apoptotic process;negative regulation of apoptotic process;protein-containing complex assembly;cellular response to mechanical stimulus;cellular response to hyperoxia;apoptotic signaling pathway;extrinsic apoptotic signaling pathway;necroptotic signaling pathway;regulation of extrinsic apoptotic signaling pathway via death domain receptors;negative regulation of extrinsic apoptotic signaling pathway via death domain receptors;positive regulation of apoptotic signaling pathway;positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
Cellular component
cytosol;plasma membrane;cell surface;integral component of membrane;nuclear body;death-inducing signaling complex;CD95 death-inducing signaling complex;membrane raft;extracellular exosome
Molecular function
transmembrane signaling receptor activity;protein binding;calmodulin binding;kinase binding;signaling receptor activity;identical protein binding